The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA)
Authors
Goyal, L.Lamarca, Angela
Strickler, J. H.
Cecchini, M.
Ahn, D. H.
Baiev, I.
Boileve, A.
Tazdait, M.
Hannan, L. M.
Jia, J. Q.
Marble, H. D.
Barzi, A.
Sahai, V.
Lennerz, J. K.
Kelley, R. K.
Bekaii-Saab, T. S.
Javle, M. M.
Uboha, N. V.
Harris, W. P.
Hollebecque, A.
Affiliation
Massachusetts General Hospital and Harvard Medical School, Boston, MAIssue Date
2020
Metadata
Show full item recordAbstract
Background: Genetic alterations in the FGFR pathway are emerging as promising therapeutic targets in CCA. The clinical and molecular features of patients (pts) with CCA harboring FGFR genetic alterations are reported here. Methods: A retrospective chart review was performed in pts with CCA who were found to have an FGFR alteration on tumor molecular profiling as part of routine care between 9/2007 and 12/2019. Data on demographics, risk factors, pathology, molecular characteristics, systemic therapies, radiographical response, time on treatment, and overall survival (OS) were collected in a multi-center collaborative effort across seven academic centers. Results: Among 135 pts with FGFR-altered CCA, the median age at diagnosis was 57 years old (range = 25-92 years), and 80 (59.3%) pts were female, 129 (95.6%) had intrahepatic CCA, and 6 (5.6%) had chronic HBV. At presentation, 28.2% of pts had resectable disease, including 65.0% with Stage I-II, 22.5% with Stage III, and 5.0% with Stage IV. At the time of initial diagnosis, CA19-9 was < 35U/mL in 42.6% of pts. Bone metastases were observed in 41 (30.6%) pts with advanced disease. FGFR2 fusions were the most common FGFR alteration (68.2%), followed by FGFR2 mutations (21.5%), FGFR3 mutations (3.7%), FGFR2 rearrangements (1.5%), FGFR1 amplification (1.5%), and FGFR2 amplification (1.5%). The most common FGFR2 fusion partners were BICC1 (28.3%), SORBS1 (4.4%), POC1B (3.3%), and TACC2 (3.3%). The median lines of palliative systemic therapies received was 3 (range = 0-8), and 40/135 (29.6%) pts received a liver-directed therapy. For the 55 (59.8%) pts with FGFR2 fusions who received gemcitabine/cisplatin as first-line palliative systemic therapy, the median time on treatment was 6.2 months (95% CI: 4.1-9.3). The median OS from time of initial diagnosis was 36.1 months (95% CI: 28.3-51.6) in the FGFR2 fusion positive cohort. Among the 92 pts with FGFR2 fusions, 70 (76.1%) pts received an FGFR inhibitor on a clinical trial; 12 (17.1%) were subsequently treated with a second FGFR inhibitor, and 58.3% stayed on the second FGFR inhibitor for ≥4 months. Pts with a BICC1 fusion partner (n = 16) had an overall response rate of 42.9% on FGFR-selective inhibitors compared to 30.8% in non-BICC1 fusion partners (n = 54). Conclusions: Pts with CCA harboring FGFR alterations were found to have a high rate of normal CA19-9, high rate of bone metastases, and short median time on treatment on first-line palliative gemcitabine/cisplatin. Additional comparative studies are necessary to evaluate these findings.Citation
Goyal L, Lamarca A, Strickler JH, Cecchini M, Ahn DH, Baiev I, et al. The natural history of fibroblast growth factor receptor (FGFR)-altered cholangiocarcinoma (CCA). Journal of Clinical Oncology. 2020;38(15_suppl):e16686-e.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2020.38.15_suppl.e16686Additional Links
https://dx.doi.org/10.1200/JCO.2020.38.15_suppl.e16686Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2020.38.15_suppl.e16686